国际多中心分析:预测高级别非肌层浸润性膀胱癌患者发生BCG无应答疾病的风险模型
本研究基于13个学术中心2211例接受足量BCG治疗的高级别Ta/T1非肌层浸润性膀胱癌患者,构建了预测BCG无应答疾病或进展的风险模型。模型纳入T1分期、再电切持续高级别或T1、多灶性、合并原位癌及WHO高级别/3级等独立预测因子,将患者分为四组,5年无BCG无应答生存率分别为88%、79%、60%和49%。
要点
- 模型区分度优于EORTC进展评分和EAU 2021分层(C指数0.68 vs 0.61 vs 0.56)。
- 独立风险因素包括T1分期、再电切持续HG/T1、多灶性、合并CIS及WHO HG/3级。
- 四风险组5年无BCG无应答生存率分别为88%、79%、60%、49%。
核心结论
- 构建了针对接受足量BCG治疗的高级别Ta/T1非肌层浸润性膀胱癌患者的风险分层模型,可个体化评估BCG失败风险并辅助临床决策。
主要发现
- 独立风险因素包括T1分期(aHR 1.52,95%CI 1.10-2.11)、再电切持续高级别或T1肿瘤(aHR 2.51,95%CI 2.06-3.06)、多灶性(aHR 1.46,95%CI 1.22-1.74)、合并原位癌(aHR 1.46,95%CI 1.21-1.77)及WHO 1973/2004/2016高级别/3级(aHR 1.56,95%CI 1.24-1.94)。
- 内部验证采用1000次bootstrap采样,乐观度极小(0.01)且校准良好。
- 模型区分度优于EORTC进展评分和EAU 2021分层(Harrell一致性指数0.68 vs 0.61 vs 0.56)。
- 随风险组升高,5年无BCG无应答生存率分别为88%、79%、60%和49%。
关键数值与推荐
- BCG无应答疾病定义依据国际膀胱癌小组和欧洲泌尿外科学会(EAU)指南。
- 风险评分将患者分为四组,5年无BCG无应答生存率分别为88%、79%、60%和49%。
临床怎么用
- 该工具可用于接受足量BCG治疗的高级别Ta/T1非肌层浸润性膀胱癌患者的个体化BCG失败风险评估,辅助临床决策。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dedicated tools estimating the risk of Bacillus Calmette-Guérin (BCG) failure among patients with high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) are lacking. OBJECTIVE: To develop a risk model predicting the development of BCG-unresponsive disease (defined according to the International Bladder Cancer Group and European Association of Urology [EAU] guidelines) or progression in patients with HG NMIBC receiving adequate BCG therapy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective multicenter study included 2211 patients who were BCG naïve with HG Ta/T1 NMIBC (±carcinoma in situ [CIS]) treated with adequate BCG therapy between January 2003 and December 2024 at 13 academic centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was time to BCG-unresponsive disease or progression to muscle-invasive/metastatic cancer. Multivariable Cox regression identified independent predictors, and a weighted clinical risk score stratified patients into four risk groups. RESULTS AND LIMITATIONS: Independent risk factors included T1 stage (adjusted hazard ratio [aHR] 1.52, 95% confidence interval [CI] 1.10-2.11), persistent HG or T1 tumor at restaging transurethral resection (aHR 2.51, 95% CI 2.06-3.06), multifocality (aHR 1.46, 95% CI 1.22-1.74), concomitant CIS (aHR 1.46, 95% CI 1.21-1.77), and World Health Organization 1973/2004/2016 HG/grade 3 (aHR 1.56, 95% CI 1.24-1.94). Internal validation via 1000 bootstrap samples revealed minimal optimism (0.01) and good calibration. The model demonstrated superior discrimination compared with the European Organization for Research and Treatment of Cancer progression score and EAU 2021 stratification (Harrell concordance index 0.68 vs 0.61 vs 0.56); 5-yr BCG-unresponsive-free survival was 88%, 79%, 60%, and 49%, respectively, across increasing risk groups. CONCLUSIONS: We developed a risk stratification model for patients with HG Ta/T1 treated with adequate BCG therapy. This tool enables individualized assessment of BCG failure risk and may support clinical decision-making.
引用
- Ślusarczyk A, Moschini M, Krajewski W, et al. Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis. Eur Urol Oncol. 2026. PMID: 42342497. doi:10.1016/j.euo.2026.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。